Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies
News release
by
Tonix Pharmaceuticals
New York
|
February 02, 2023 12:15 PM Eastern Standard Time
Tonix Pharmaceuticals CEO Seth Lederman joined Proactive's Natalie Stoberman to discuss the exclusive license of potential monoclonal antibodies from Curia Global, a leading contract research, development and manufacturing organization.
Lederman said Tonix has obtained an exclusive license for the development of three humanized murine monoclonal antibodies for the treatment or prophylaxis of SARS-CoV-2 infection.
Contact Details
Proactive Studio
+1 347-449-0879
